ERBB2 and breast cancer: In our study, 11 patients (32.3%) had neither SLNB nor axillary node clearance; six patients (17.6%) declined any form of axillary surgery, while five patients (14.7%) had clinically node-negative, hormone receptor-positive and HER2 receptor-negative breast cancers.